Virtu Financial LLC Acquires Shares of 3,110 Vaxcyte, Inc. (NASDAQ:PCVX)

Virtu Financial LLC bought a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the 3rd quarter, Holdings Channel reports. The institutional investor bought 3,110 shares of the company’s stock, valued at approximately $355,000.

Several other institutional investors and hedge funds also recently made changes to their positions in PCVX. Janus Henderson Group PLC grew its stake in shares of Vaxcyte by 23.1% during the third quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company’s stock worth $1,247,954,000 after purchasing an additional 2,052,989 shares during the period. RA Capital Management L.P. boosted its holdings in Vaxcyte by 5.9% during the third quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company’s stock worth $992,914,000 after buying an additional 485,436 shares during the last quarter. State Street Corp grew its position in shares of Vaxcyte by 1.1% during the 3rd quarter. State Street Corp now owns 3,405,743 shares of the company’s stock worth $389,174,000 after buying an additional 38,596 shares during the period. Geode Capital Management LLC increased its stake in shares of Vaxcyte by 10.6% in the 3rd quarter. Geode Capital Management LLC now owns 2,700,782 shares of the company’s stock valued at $308,675,000 after acquiring an additional 259,010 shares during the last quarter. Finally, Driehaus Capital Management LLC raised its position in shares of Vaxcyte by 3.6% in the 2nd quarter. Driehaus Capital Management LLC now owns 1,934,747 shares of the company’s stock valued at $146,093,000 after acquiring an additional 66,940 shares during the period. Institutional investors own 96.78% of the company’s stock.

Insider Transactions at Vaxcyte

In related news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the transaction, the chief financial officer now owns 90,383 shares in the company, valued at approximately $10,479,005.02. This represents a 8.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Grant Pickering sold 2,366 shares of the firm’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $103.89, for a total transaction of $245,803.74. Following the completion of the transaction, the chief executive officer now directly owns 137,398 shares of the company’s stock, valued at approximately $14,274,278.22. This trade represents a 1.69 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 117,830 shares of company stock valued at $12,600,310 in the last ninety days. 3.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on PCVX shares. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Leerink Partners boosted their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a report on Tuesday, September 3rd. Bank of America raised their price objective on Vaxcyte from $101.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Mizuho boosted their target price on Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Finally, Jefferies Financial Group increased their price target on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Trading Up 2.0 %

Shares of NASDAQ PCVX opened at $89.49 on Tuesday. The company has a fifty day moving average price of $100.73 and a 200 day moving average price of $91.98. Vaxcyte, Inc. has a 1-year low of $53.83 and a 1-year high of $121.06. The firm has a market cap of $11.15 billion, a PE ratio of -19.45 and a beta of 0.94.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.10) by $0.27. During the same period in the prior year, the company earned ($0.91) EPS. Equities research analysts forecast that Vaxcyte, Inc. will post -4.14 EPS for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.